光谱学在泌尿生殖系统恶性肿瘤诊断、分期及治疗中的应用。
Applications of spectroscopy in diagnosis, staging, and treatment of urologic malignancies.
作者信息
Seltz Lara M, Herrell S Duke
机构信息
aDepartment of Urologic Surgery bDepartments of Biomedical and Mechanical Engineering cVanderbilt Institute for Surgical Engineering (VISE), Nashville, Tennessee, USA.
出版信息
Curr Opin Urol. 2016 May;26(3):259-63. doi: 10.1097/MOU.0000000000000281.
PURPOSE OF REVIEW
To review the scientific literature on clinical applications of spectroscopy within urologic oncology. Specifically, we address the role of spectroscopy as a novel intraoperative or intraprocedural modality for the management of urothelial carcinoma, renal cell carcinoma, and prostate adenocarcinoma.
RECENT FINDINGS
Recent studies have demonstrated that spectroscopy models, suitable for translation to in-vivo clinical use, can differentiate between benign parenchyma and malignant tissue for urothelial carcinoma, renal cell carcinoma, and prostate adenocarcinoma. Recent work has also established spectroscopy as a feasible modality to detect biologically aggressive high-risk disease and classify natural biomarkers.
SUMMARY
Spectroscopy has the ability to objectively diagnose and stage malignancies in real time without tissue or cellular disruption. In the future, additional in-vivo studies will be needed to demonstrate that current models remain robust under physiological conditions.
综述目的
回顾关于光谱学在泌尿肿瘤学临床应用的科学文献。具体而言，我们探讨光谱学作为一种新型术中或术中操作方式在尿路上皮癌、肾细胞癌和前列腺腺癌管理中的作用。
最新发现
近期研究表明，适用于转化为体内临床应用的光谱学模型能够区分尿路上皮癌、肾细胞癌和前列腺腺癌的良性实质与恶性组织。近期工作还将光谱学确立为一种检测具有生物学侵袭性的高危疾病并对天然生物标志物进行分类的可行方式。
总结
光谱学能够在不破坏组织或细胞的情况下实时客观地诊断恶性肿瘤并进行分期。未来，需要更多的体内研究来证明当前模型在生理条件下仍保持稳健。
Zotero 插件